Osa, ph, and ild: Interacting comorbidities.

Luca Moretti*

Department of Pulmonology, University of Milan, Italy

Introduction

This systematic review and meta-analysis highlights the high prevalence of obstructive sleep apnea (OSA) in patients with interstitial lung disease (ILD), finding it to be significantly higher than in the general population. It underscores the need for routine OSA screening in ILD patients due to its potential impact on quality of life and disease progression, though further research is needed on its specific management in this comorbid population.[1].

This review delves into the significant overlap between obstructive sleep apnea (OSA) and idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). It discusses how OSA can exacerbate hypoxia, worsen symptoms, and potentially accelerate disease progression in ILD patients, emphasizing the importance of screening and tailored management strategies for this common comorbidity.[2].

This review identifies and discusses various risk factors contributing to the development of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). It covers genetic predispositions, disease severity, hypoxemia, and other comorbidities, providing insights into the complex interplay driving PH in this patient group and highlighting the need for early detection and personalized management.[3].

This review comprehensively explores the various forms of sleep-disordered breathing (SDB), including obstructive sleep apnea (OSA) and central sleep apnea, in the context of interstitial lung disease (ILD). It highlights the high prevalence of SDB in ILD patients, its detrimental impact on gas exchange and quality of life, and the diagnostic and therapeutic challenges associated with its management.[4].

This study investigates the association between obstructive sleep apnea (OSA) and pulmonary hypertension (PH) in patients with idiopathic pulmonary fibrosis (IPF). It finds a significant correlation, suggesting that OSA might be a contributing factor to PH development or progression in IPF patients, underscoring the importance of screening for and managing OSA in this vulnerable population.[5].

This review explores the high prevalence of sleep-disordered breathing (SDB) in patients with fibrotic interstitial lung diseases (fILDs) and its clinical implications. It discusses how SDB, particularly obstructive sleep apnea, can worsen hypoxemia, increase symptom burden, and negatively impact quality of life in fILD patients, advocating for systematic assessment and treatment.[6].

This systematic review synthesizes current evidence on sleep disturbances in patients with interstitial lung diseases (ILDs), covering various sleep disorders including sleep apnea, insomnia, and restless legs syndrome. It highlights the significant burden of poor sleep quality and quantity on ILD patients' well-being and disease progression, emphasizing the need for comprehensive assessment and management of sleep in this population.[7].

This study investigates the relationship between obstructive sleep apnea (OSA) and pulmonary hypertension (PH) in patients with interstitial lung disease (ILD), concluding that OSA acts as an independent risk factor for PH development in this population. It underscores the critical importance of early screening and effective management of OSA to mitigate the progression of PH and improve outcomes for ILD patients.[8].

This review article provides an overview of pulmonary hypertension (PH) in the context of interstitial lung disease (ILD), covering its epidemiology, pathophysiology, diagnostic challenges, and current therapeutic approaches. It emphasizes the significant impact of PH on morbidity and mortality in ILD patients and highlights the ongoing need for improved screening and management strategies.[9].

This review explores the complex interplay between cardiac and pulmonary systems in interstitial lung disease (ILD), specifically focusing on how sleep and sleep-disordered breathing can exacerbate these interactions. It discusses the impact of nocturnal hypoxemia and increased intrathoracic pressures on right ventricular function and pulmonary vascular resistance, underscoring the importance of considering sleep health in the holistic management of ILD.[10].

Conclusion

Obstructive Sleep Apnea (OSA) and other forms of Sleep-

***Correspondence to:** Luca Moretti, Department of Pulmonology, University of Milan, Italy. E-mail: luca.moretti@pulmonologyit.it

Received: 05-Apr-2024, Manuscript No. AARRP-24-164; **Editor assigned:** 09-Apr-2024, Pre QC No. AARRP-24-164 *(PQ)*; **Reviewed:** 29-Apr-2024, QC No. AARRP-24-164; **Revised:** 08-May-2024, Manuscript No. AARRP-24-164 *(R)*; **Published:** 17-May-2024, DOI: 10.35841/aarrp-5.1.164

Citation: Moretti L. Osa, ph, and ild: Interacting comorbidities. Res Rep Pulomonol. 2024;05(01):164.

Disordered Breathing (SDB) are highly prevalent in patients with Interstitial Lung Disease (ILD), including Idiopathic Pulmonary Fibrosis (IPF), significantly exceeding rates in the general population. This comorbidity profoundly impacts ILD patients by exacerbating hypoxia, worsening symptoms, and accelerating disease progression, ultimately diminishing their quality of life. The need for routine OSA screening and tailored management strategies in ILD patients is therefore critical. A significant concern is the strong association between OSA and Pulmonary Hypertension (PH) in ILD. Studies reveal OSA as an independent risk factor for PH development, highlighting that effective OSA management can mitigate PH progression and improve patient outcomes. PH itself in ILD is influenced by a complex interplay of genetic factors, disease severity, and hypoxemia, demanding early detection and personalized treatment. Beyond OSA, a broader spectrum of sleep disturbances contributes to the burden on ILD patients, underscoring the necessity for comprehensive sleep assessment. Ultimately, understanding and addressing these cardiopulmonary interactions, particularly the role of nocturnal hypoxemia and SDB, is vital for a holistic approach to ILD care, with ongoing research aiming to refine specific management strategies for these complex comorbidities.

References

1. Vimal B., Ankit S., Ammar A. Obstructive Sleep Apnea in Interstitial Lung Disease: A Systematic Review and Meta-Analysis. *J Clin Sleep Med.* 2024;20:119-128.
2. Annett K., Sven V., *Dirk G. Obstructive sleep apnea in idiopathic pulmonary fibrosis and other interstitial lung diseases. J Clin Med.* 2023;12:2988.
3. Lucia Z., Fabio P., *Mattia Z. Risk factors for pulmonary hypertension in interstitial lung disease. Front Med* (Lausanne). 2023;10:1251025.
4. Kajal K., Krishnan R., Shruti S. Sleep-Disordered *Breathing in Interstitial Lung Disease. Lung.* 2022;200:749-760.
5. Manabu S., Masato H., *Hideaki Y. Obstructive sleep apnea is associated with pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration.* 2020;99:147-156.
6. Eleonora B., Federico M., Sara B. Prevalence and impact of sleep-disordered breathing in fibrotic interstitial lung diseases. *Sleep Med.* 2022;94:86-93.
7. Adam M., Szymon W., Maciej G. Sleep in patients with interstitial lung diseases: a systematic review. *Adv Respir Med.* 2021;89:647-657.
8. Xinglin Z., Ruiming D., *Chong W. Obstructive Sleep Apnea is an Independent Risk Factor for Pulmonary Hypertension in Interstitial Lung Disease. Front Cardiovasc Med.* 2022;9:969145.
9. Mia SK., Said BS., *Hossein AG. Pulmonary Hypertension in Interstitial Lung Disease. Diagnostics* (Basel). 2023;13:3379.
10. Karen H., Julian F., Sophie D. Cardiopulmonary Interactions in Interstitial Lung Disease: *The Role of Sleep. J Clin Med.* 2019;8:1475.

Citation: *Moretti L. Osa, ph, and ild: Interacting comorbidities. Res Rep Pulomonol. 2024;05(01):164.*